# Study of Safety, Tolerability & Efficacy in Cystic Fibrosis Patients With Abnormal Glucose Tolerance

> **NCT02955888** · PHASE2 · TERMINATED · sponsor: **Liminal BioSciences Ltd.** · enrollment: 11 (actual)

## Conditions studied

- Cystic Fibrosis

## Interventions

- **DRUG:** PBI4050
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02955888
- **Lead sponsor:** Liminal BioSciences Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2017-01-03
- **Primary completion:** 2018-02
- **Final completion:** 2018-02
- **Target enrollment:** 11 (ACTUAL)
- **Why stopped:** Unsatisfactory rate of recruitment
- **Last updated:** 2020-12-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02955888

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02955888, "Study of Safety, Tolerability & Efficacy in Cystic Fibrosis Patients With Abnormal Glucose Tolerance". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT02955888. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*